Adalimumab - CISMeF

Preferred Label : Adalimumab;

MeSH definition : A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.;

CISMeF synonym : D2E7 Antibody;

MeSH hyponym : humira; Antibody, D2E7;

Wikipedia link : https://en.wikipedia.org/wiki/Adalimumab;

Is substance : O;

UNII : FYS6T7F842;

Details

Origin ID

D000068879;

UMLS CUI

C1122087;

ATC code(s)
- adalimumab [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- ADA Gene [NCIt concept]
- Adalimumab [ICD-11 Extension code]
- Adenosine Deaminase [NCIt concept]
- Adenosine deaminase [LOINC component]
- Adenosine deaminase [OMIM gene]
- Anti-Drug Antibody [NCIt concept]
- adalimumab [EMDN type]
- adalimumab [medical devices type]
- adenosine deaminase [SNOMED Notion]
CISMeF manual mappings
- Adalimumab [NCIt concept]
- Adalimumab (substance) [SNOMED CT concept]
- adalimumab [Substance BNPC]
Exact mapping(s) to DCI
- adalimumab [International Nonproprietary Name]
False automatic mappings
- Adangme Language [NCIt concept]
- American Diabetes Association [NCIt concept]
- adenosine deaminase [ORDO Gene]
Pharmacological action(s)
- Tumor Necrosis Factor Inhibitors [MeSH Descriptor]
- antirheumatic agents [MeSH Descriptor]
Record concept(s)
- Adalimumab-adbm [MeSH concept]
- Adalimumab-atto [MeSH concept]
- Amjevita [MeSH concept]
- Cyltezo [MeSH concept]
- D2E7 Antibody [MeSH concept]
- adalimumab [MeSH concept]
- humira [MeSH concept]
Related MeSH Supplementary Concept(s)
- ABP 501 [MeSH Supplementary Concept]
- BI 695501 [MeSH Supplementary Concept]
- FKB327 [MeSH Supplementary Concept]
- GP2017 [MeSH Supplementary Concept]
- PF-06410293 [MeSH Supplementary Concept]
- adalimumab biosimilar HS016 [MeSH Supplementary Concept]
See also
- tumor necrosis factor-alpha [MeSH Descriptor]
See also inter- (CISMeF)
- Product containing adalimumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Adalimumab [NCIt concept]
- Adalimumab [LOINC component]
- Adalimumab (substance) [SNOMED CT concept]
- Product containing adalimumab (medicinal product) [SNOMED CT concept]
- adalimumab [ATC Code]
- adalimumab [Substance BNPC]
- adalimumab [International Nonproprietary Name]
Validated automatic mappings to BTNT
- adalimumab [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients